Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Director Sells $3,135,953.50 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Director Peter Neupert sold 124,690 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $25.15, for a total transaction of $3,135,953.50. Following the completion of the sale, the director owned 130,625 shares of the company’s stock, valued at $3,285,218.75. This trade represents a 48.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Adaptive Biotechnologies Price Performance

ADPT stock opened at $25.99 on Friday. The stock has a market cap of $4.15 billion, a PE ratio of -63.39 and a beta of 2.08. Adaptive Biotechnologies Corporation has a 12 month low of $12.00 and a 12 month high of $26.16. The company has a 50-day moving average price of $22.06 and a 200 day moving average price of $17.35. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The firm had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same period last year, the company earned ($0.17) earnings per share. Equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. reduced their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Piper Sandler boosted their price objective on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Morgan Stanley increased their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Finally, Guggenheim lifted their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.42.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently modified their holdings of the stock. Nykredit A S bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $31,000. Headlands Technologies LLC purchased a new stake in shares of Adaptive Biotechnologies in the second quarter valued at approximately $208,000. Susquehanna Advisors Group Inc. bought a new position in Adaptive Biotechnologies in the second quarter worth approximately $3,951,000. Cookson Peirce & Co. Inc. bought a new position in Adaptive Biotechnologies in the second quarter worth approximately $868,000. Finally, Wellington Management Group LLP increased its holdings in Adaptive Biotechnologies by 53.2% during the 2nd quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock worth $126,799,000 after purchasing an additional 2,053,944 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.